

		ALAPIS HOLDING INDUSTRIAL AND COMMERCIAL SOCIETE ANONYME OF PHARMACEUTICAL AND CHEMICAL PRODUCTS			
		Company's Number in the Register of Societes Anonymes: 8057/06/08/011			
		REGISTERED ADDRESS : 2, AFTOKRATOROS NIKOLAOU STR, P.C 17671 ATHENS			
		DATA AND INFORMATION FOR THE PERIOD 1 JANUARY 2010 TO 30 SEPTEMBER 2010			
		According to Decision 4/507/28.04.2009 of the Capital Market Committee			
The following data and information aim at providing general information on the financial standing and the financial results of ALAPIS S.A.. We, therefore, recommend the reader, before proceeding to any kind of investment or other transaction with the company, to look to the company's website www.alapis.eu, where all periodical financial statements under IFRS together with the Audit report of the external auditor (when necessary) are presented.					
COMPANY DETAILS					
Website :	www.alapis.eu				
Approval date for issuing by the Board of Directors :	29 November 2010				
STATEMENT OF FINANCIAL POSITION (amounts in thousands €)					
	The Group		The Company		
	30.09.2010	31.12.2009	30.09.2010 31.12.2009		
ASSETS					
Property, plant and equipment	1,550,227	1,669,714	1,498,362 1,580,386		
Investment in property, plant and equipment	46,125	25,544	46,125 25,476		
Intangible assets	848,210	879,442	656,763 606,688		
Other non current assets	17,969	18,227	313,988 492,904		
Inventories	119,998	164,869	30,778 39,922		
Trade receivables	399,309	274,983	458,490 351,705		
Other current assets	211,601	334,680	148,870 214,889		
Non current assets available for sale	0	0	0 0		
TOTAL ASSETS	3,193,440	3,367,458	3,153,376 3,311,971		
EQUITY AND LIABILITIES					
Share capital	588,360	588,360	588,360 588,360		
Other equity items	1,375,410	1,359,809	1,404,551 1,401,538		
Total owners' equity (a)	1,963,770	1,948,169	1,992,911 1,989,898		
Non controlling interests (b)	75	92	0 0		
Total equity (c) = (a) + (b)	1,963,845	1,948,261	1,992,911 1,989,898		
Long term borrowings	735,000	735,000	735,000 735,000		
Provisions / other long term liabilities	155,654	153,674	127,719 121,974		
Short-term borrowings	92,296	146,187	85,000 141,001		
Other short term liabilities	246,645	384,335	212,745 324,098		
Non current liabilities available for sale	0	0	0 0		
Total liabilities (d)	1,229,595	1,419,196	1,160,464 1,322,073		
TOTAL EQUITY AND LIABILITIES (c)+(d)	3,193,440	3,367,458	3,153,376 3,311,971		
STATEMENT OF COMPREHENSIVE INCOME (amounts in thousands €)					
	The Group				
	1.1. - 30.09.2010	1.1. - 30.09.2009			
	Continuing operations	Discontinued operations	Continuing operations Discontinued operations Total		
Revenue	623,709	95,680	719,389 560,047 772,755		
Gross profit/(loss)	205,475	46,581	252,056 192,365 301,700		
Profit before tax, financial and investing results (EBIT)	86,348	1,837	88,186 118,183 170,835		
Profit/(loss) before tax	47,917	4,581	52,499 83,643 126,017		
Profit/(loss) (a)	26,474	195	26,668 34,793 103,102		
Owners of the parent	26,560	195	26,754 68,814 103,607		
Non-controlling interests	(86)	0	(86) (505) 0		
Other comprehensive income (net of tax) (b)	352	0	352 (24,017) 0		
Total comprehensive income (net of tax) (a) + (b)	26,826	195	27,021 44,292 34,793		
Owners of the parent	26,905	195	27,100 44,799 34,793		
Non-controlling interests	(79)	0	(79) (507) 0		
Net profit per share - basic (in €)	0.1124	0.0008	0.1133 0.5916 0.2991		
Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA)	196,893	14,520	211,414 187,542 64,146		
	The Group				
	1.7. - 30.09.2010	1.7. - 30.09.2009			
	Continuing operations	Discontinued operations	Continuing operations Discontinued operations Total		
Revenue	200,982	0	200,982 180,471 66,183		
Gross profit/(loss)	65,097	0	65,097 74,528 24,347		
Profit before tax, financial and investing results (EBIT)	14,816	0	14,816 34,903 16,048		
Profit/(loss) before tax	3,020	0	3,020 24,129 11,266		
Profit/(loss) (a)	1,452	0	1,452 16,387 12,054		
Owners of the parent	1,472	0	1,472 16,382 12,054		
Non-controlling interests	(20)	0	(20) 5 0		
Other comprehensive income (net of tax) (b)	18	0	18 (24,234) 0		
Total comprehensive income (net of tax) (a) + (b)	1,471	0	1,471 (7,847) 12,054		
Owners of the parent	1,491	0	1,491 (7,852) 12,054		
Non-controlling interests	(20)	0	(20) 5 0		
Net profit per share - basic (in €)	0.0062	0.0000	0.0062 0.1347 0.0991		
Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA)	58,271	0	58,271 63,892 16,751		
	The Company				
	1.1. - 30.09.2010	1.1. - 30.09.2009			
	Continuing operations	Discontinued operations	Continuing operations Discontinued operations Total		
Revenue	256,895	34,070	290,964 167,733 121,623		
Gross profit/(loss)	134,387	9,623	144,010 51,663 176,354		
Profit before tax, financial and investing results (EBIT)	66,330	(5,442)	60,888 80,931 112,703		
Profit/(loss) before tax	32,557	(4,278)	28,279 57,071 28,323		
Profit/(loss) (a)	18,884	(4,534)	14,351 47,894 69,705		
Owners of the parent	18,884	(4,534)	14,351 47,894 21,811		
Non-controlling interests	0	0	0 0 0		
Other comprehensive income (net of tax) (b)	0	0	0 (24,007) 0		
Total comprehensive income (net of tax) (a) + (b)	18,884	(4,534)	14,351 23,887 21,811		
Owners of the parent	18,884	(4,534)	14,351 23,887 21,811		
Non-controlling interests	0	0	0 0 0		
Net profit per share - basic (in €)	0.0799	(0.0192)	0.0608 0.4117 0.1875		
Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA)	145,484	127	145,611 125,652 38,176		
	The Company				
	1.7. - 30.09.2010	1.7. - 30.09.2009			
	Continuing operations	Discontinued operations	Continuing operations Discontinued operations Total		
Revenue	72,367	0	72,367 49,825 43,312		
Gross profit/(loss)	28,317	0	28,317 44,382 9,943		
Profit before tax, financial and investing results (EBIT)	8,817	0	8,817 17,412 4,751		
Profit/(loss) before tax	1,395	0	1,395 10,237 1,301		
Profit/(loss) (a)	1,060	0	1,060 4,699 1,545		
Owners of the parent	1,060	0	1,060 4,699 1,545		
Non-controlling interests	0	0	0 0 0		
Other comprehensive income (net of tax) (b)	0	0	0 (24,007) 0		
Total comprehensive income (net of tax) (a) + (b)	1,060	0	1,060 (19,308) 1,545		
Owners of the parent	1,060	0	1,060 (19,308) 1,545		
Non-controlling interests	0	0	0 0 0		
Net profit per share - basic (in €)	0.0045	0.0000	0.0045 0.0386 0.0127		
Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA)	26,628	0	26,628 34,105 4,971		
ADDITIONAL DATA AND INFORMATION (amounts in thousands €)					
1. The companies included in the consolidated financial statements, together with their registered addresses, the consolidation method in the financial statements of the Company and their share of participation are analyzed in note 5 of the financial statements and their tax unaudited FYs are analyzed in note 13 of the financial statements.					
2. During the current period ALAPIS SA proceeded to the following business activities: On February 2010, acquired the 100 % stake of the company GEROLYMATOS INC, which has its headquarters in New York and is activated mainly in the distribution of OTC products and cosmetics in the American market. On April 2010, acquired the remaining 8.80% of the company IPIROFARM SA following which ALAPIS SA now controls 100.00% of the share capital of the company. On June 2010, proceeded with the disposal of the companies GEROLYMATOS PRESTIGE SPA'S BEAUTY SALON SA, GEROLYMATOS COSMETICS SA, SHISEIDO HELLAS SA, BEAUTY WORKS SA, PROVET SA, GEROLYMATOS ANIMAL HEALTH SA, ALAPIS MEDICAL AND DIAGNOSTICS SA, ALMEDIA PHARMACEUTICALS SA and KTINIATRIKI – PROMITHEUTIKI SA. Finally the Company proceeded in the establishment of the company HSP UNIPESOAAL LDA based in Portugal with core objective the distribution of pharmaceutical products.					
3. The financial statements of the Company are not included in consolidated financial statements of any other company.					
4. There are no litigation matters which may have material impact on the financial position of the Group and the Company. The amount of provisions for any litigation matters on September 30, 2010 amounts up to € 17,873 for the Group and € 16,778 for the Company. The provisions for tax unaudited FYs on September 30, 2010 amount up to € 5,945 for the Group and € 2,404 for the Company.					
The extraordinary tax expenses provision according to L 3845/2010 which are included in current period Net Profits amounts to € 10,808 for the Group and € 6,868 for the Company.					
CASH FLOW STATEMENT (amounts in thousands €)					
	The Group		The Company		
	1.1. - 30.09.2010	1.1. - 30.09.2009	1.1. - 30.09.2010 1.1. - 30.09.2009		
Operating activities					
Profits before taxes (continuous operation)	47,917	83,643	32,557 57,071		
Profits before taxes (discontinuous operation)	4,581	42,374	(4,278) 28,323		
Plus/ less adjustments for:					
Depreciation and amortization	110,545	69,360	79,154 44,721		
Gain/ Loss from disposal of assets	(205)	(118)	(176) 79		
Provisions	1,474	662	(5,562) (2,830)		
Exchange differences	(405)	2,523	(110) (4)		
Results (income, expenses, gain, loss) from investing activity	4,611	(977)	4,109 371		
Interest expense	35,562	35,517	28,500 26,938		
Plus/less changes in working capital:					
Decrease / (increase) of inventories	(9,817)	(19,507)	(2,135) (10,064)		
Decrease / (increase) of trade receivables	(138,044)	(130,274)	(81,071) (195,794)		
Decrease / (increase) of other receivables	(21,672)	29,086	(22,757) 16,625		
Decrease / Increase of trade liabilities (excluding borrowings)	(55,547)	(62,816)	(70,797) (4,281)		
Decrease / Increase of other liabilities(excluding borrowings)	(39,103)	20,779	(36,387) 76,596		
Less:					
Interest paid	(32,676)	(42,235)	(29,034) (31,342)		
Taxes paid	(8,999)	(3,855)	(6,746) (1,022)		
Operating cash flow from discontinued operation	(17,410)	43,179	6,391 2,389		
Net cash flows from operating activities (a)	(119,188)	67,340	(107,751) 7,477		
Investing activities					
(Acquisition)/Disposal of subsidiaries, related, joint ventures and other investments	(67)	(72,073)	(4,050) (130,387)		
Purchase/Disposal of assets	(92,259)	(119,472)	(61,907) (43,006)		
Interest received	348	1,054	230 691		
Proceeds from grants / Guarantees paid	237	(19)	(1,046) 104		
Investing cash flow from discontinued operation	142,529	(91,197)	145,335 (56,303)		
Net cash flows from investing activities (b)	50,788	(281,707)	78,562 (228,903)		
Financing activities					
Share capital issued (net of expenses)	0	423,063	0 423,063		
Proceeds/(Payments) from borrowings	(50,472)	(114,695)	(56,000) (50,273)		
Proceeds from / (repayments) of finance lease	(2,711)	16,232	(1,553) (220)		
Dividends paid	(11,333)	(10,125)	(11,333) (9,999)		
Treasury shares / Gain from disposal of share capital's issue rights	0	4,006	0 4,006		
Financing activities from discontinued operation	573	(476)	0 0		
Net cash flows from financing activities (c)	(63,942)	318,005	(68,886) 366,579		
Net increase in cash and cash equivalents (a)+(b)+(c)	(132,342)	103,638	(98,076) 145,153		
Cash and cash equivalents at beginning of the period	216,398	208,679	158,426 121,305		
Cash contributed by merged entities	0	0	0 9,491		
Cash and cash equivalents at end of the period	84,055	312,317	60,350 275,950		
STATEMENT OF CHANGES IN EQUITY (amounts in thousands €)					
	The Group		The Company		
	30.09.2010	30.09.2009	30.09.2010 30.09.2009		
Equity balance at the beginning of the period (1.1.2010 and 1.1.2009 respectively)	1,948,261	1,546,377	1,989,898 1,528,323		
Total comprehensive income (net of tax) (continuing and discontinued operations)	27,021	79,085	14,351 45,698		
Sale of subsidiaries	0	2,175	0 0		
Dividends	(11,338)	(10,062)	(11,338) (9,999)		
Acquisition of subsidiaries	(100)	(67,324)	0 0		
Merger of subsidiaries	0	0	0 2,550		
Issue of Share Capital	0	451,076	0 451,076		
Equity balance at the end of the period (30.09.2010 and 30.09.2009 respectively)	1,963,845	2,001,326	1,992,911 2,017,648		
ADDITIONAL DATA AND INFORMATION (continuation) (amounts in thousands €)					
The Group and the Company have made no other provisions.					
5. The number of employees at the end of current period for the Group and the Company is 1,996 and 951 respectively and for the period ended on September 30, 2009 was 2,917 and 781 for the Group and the Company respectively.					
6. The accumulated amounts of the transactions and the balances on September 30, 2010 between the Company and the associated companies as defined in IAS 24, are as follows :					
	GROUP	COMPANY			
a) Income :	0	134,515			
b) Expenses:	0	24,150			
c) Receivables:	0	148,832			
d) Liabilities:	0	46,432			
e) Rewards to Managers and Members of the Board of Directors	1,554	1,554			
f) Receivables from Managers and Members of the Board of Directors	0	0			
g) Liabilities to Managers and Members of the Board of Directors	55	55			
7. In the consolidated financial statements for period ended September 30, 2009 the following companies are not consolidated to the Group: SAMBROOK MED SA, ALMEDIA PHARMACEUTICALS SA, MEDSYSTEMS SA, SHISEIDO HELLAS SA, GENESIS ILAC SA, GEROLYMATOS INC and HSP UNIPESOAAL LDA. In the consolidated financial statements for the period ended September 30, 2010 GEROLYMATOS INC and HSP UNIPESOAAL LDA are fully consolidated to the Group for the first time since their acquisition and establishment date respectively. In addition GENESIS ILAC SA, which was consolidated on December 31, 2009 using the equity method, is consolidated to the Group via proportional method. It is noted that within 2010 was concluded the owners' agreement for joint control of GENESIS ILAC SA. In the consolidated financial statements for period ended September 30, 2010 the following companies are not consolidated to the Group: GLIKEIA IGIEIA SA, GLIKEIA GEFIS SA, PROIONTA EBK SA, CERTIFIED ORGANIC PRODUCTS LTD, THERAPEFTIKI SA, EBK SA, LYD SA, DALL SA, DILACO LTD and					